COO The Cooper Companies, Inc.
USHealthcareAs of 2026-10-08
Why COO matters now
The Cooper Companies, Inc. (COO) is a US stock in Healthcare. The latest InvestLog snapshot shows $54.30 with -0.82% on the session and $10.59B in market capitalization; recent performance reads 1-month +7.26% and YTD -19.58%.
The latest financial table shown here is Q2 2026, with revenue of $1.08B, net income of $-77.9M, and EPS of $-0.40. Investors can compare that operating picture with valuation signals such as P/E 34.61 and FCF yield 4.4%.
InvestLog's latest related AI research is a Earnings Analysis note titled "COO earnings call: We expect the Q4 non-GAAP effective tax rate to be roughly 16%, resulting in non-GAAP EPS of $1.05 to $1.09. We expect around $170 million of free cash flow, excluding litigation-related payments of roughly $272 million.". The latest indexable market news headline is "Cooper Companies Director Kurzius Buys 10,000 Shares for $539,100. What Does This Insider See in Shares?" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $85.50; recent insider activity includes Rosebrough Walter M Jr filing M-Exempt; recent congressional disclosure data includes Gilbert Cisneros Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
34.61
PEG
—
P/B
1.56
P/S
3.04
EV/EBITDA
17.53
DCF Value
$58.83
FCF Yield
4.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.4%
Operating Margin
11.8%
Net Margin
5.6%
ROE
2.8%
ROA
1.9%
ROIC
2.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1.08B | $-77.9M | $-0.40 |
| Q1 2026 | $1.02B | $130.8M | $0.66 |
| Q4 2025 | $1.07B | $84.6M | $0.43 |
| FY 2025 | $4.09B | $374.9M | $1.87 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$80.33
Target (Median)
$85.50
Target Range
$61.00 - $98.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
COO earnings call: We expect the Q4 non-GAAP effective tax rate to be roughly 16%, resulting in non-GAAP EPS of $1.05 to $1.09. We expect around $170 million of free cash flow, excluding litigation-related payments of roughly $272 million.库珀医疗 (COO) 电话会：我们预计第四季度非GAAP实际税率约为16%，对应非GAAP每股收益1.05美元至1.09美元。我们预计自由现金流约1.7亿美元，不含约2.72亿美元的诉讼相关支出。
Brian Andrews: We expect the Q4 non-GAAP effective tax rate to be roughly 16%, resulting in non-GAAP EPS of $1.05 to $1.09. We expect around $170 million of free cash flow, excluding litigation-related payments of roughly $272 million.布莱恩·安德鲁斯：我们预计第四季度非GAAP实际税率约为16%，对应非GAAP每股收益1.05美元至1.09美元。我们预计自由现金流约1.7亿美元，不含约2.72亿美元的诉讼相关支出。
COO earnings release — EPS beat +2.7% · revenue missed -2.9%库珀医疗 (COO) 财报发布 — EPS 高于预期+2.7% · 营收 低于预期-2.9%
The Cooper Companies, Inc. reported EPS $1.15 vs $1.12 estimate and revenue $1.1B vs $1.1B estimate.库珀医疗 公布财报：EPS $1.15 vs $1.12 预期，营收 $1.1B vs $1.1B 预期。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
0.87
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.